Virtual Invest Meetup,
May 20th, 2021.
One of the purposes of Unicorn Lab is promoting beneficial cooperation and partnership between entrepreneurs and investors from the HealthTech, BioTech Industry.
We invite you to join our Virtual Invest Meetup. It is the networking event where top tear Investors meet innovation Startups working to promote Longevity and Health spans.
Date and Time: May 20th, 10 am - 1 pm PT | 1 pm - 4 pm ET | 12 pm - 3 pm CT
It is a great opportunity to learn from Industry Experts and gain life-changing knowledge and insight as well as to find Innovative Solutions and Technologies for your investment portfolio.
The Meetup will start with the Panel Discussion "The Hottest Trends in HealthTech Investment". Experienced and renowned Venture Capital Investors will describe the topic from their perspectives.
The second part will be dedicated to the Presentations of selected HealthTech, LongevityTech, and BioTech Startups. Each entrepreneur will have 10 minutes for their Pitch which will be followed by a Q&A session with invited VCs.
If you are interested in presenting your Startup at the Meetup, please Apply and we will get back to you with feedback
We are looking forward to meeting you!
Julianne currently leads healthcare investing at Plug and Play where she focuses on digital solutions for patients, provides, and pharma. Plug and Play is a global innovation platform that includes venture capital, business development programs, and corporate innovation. In 2019, Pitchbook named Plug and Play the 2nd most active investor in the US and the 5th most active investor in healthcare services and systems. Julianne is particularly interested in preventive medicine, femtech, and digital therapeutics as well as impact investing. Her recent investments include Helium Health (healthcare software solutions for emerging markets), Rapicare (healthcare supply chain solution in Brazil), and Hyfe (AI for cough detection and analysis). Earlier in her career, Julianne worked on therapeutics investing.
Allan joined the Medtech Convergence Fund as a Venture Partner in 2020. MCF is focused on the shift in therapy from intervention to prevention, invasive to non-invasive, and hospitals to the home, improving patient access while lowering the costs of managing disease. MCF is within the $3B family of funds managed by SV Health Investors.
Allan is a founder of Life Science Angels (www.lifescienceangels.org), the largest and most well-known early-stage investment group focused solely on emerging biotech, genomic, medical device, diagnostic and mobile health companies (LSA) and comprised entirely of industry veterans. LSA has invested over $75M in 70 portfolio companies and achieved 24 positive exits, and was named the Top Angel Investment Group in the United States by industry analytical source CB Insights (https://www.cbinsights.com/blog/top-angel-groups-mosaic/).
Previously, Allan was co-founder and Managing Partner of Emergent Medical Partners, a $90M venture fund, focused on medical device and diagnostics. Investments included eValve (Abbott); Nanostim (acq St Jude); CyberHeart (acq Varian); Crux (acq Volcano); StimWave and Relievant.
Allan is also Chairman of FundamentalVR, the leader in utilizing kinesthetic haptic feedback and VR to enable the commercial introduction of new medical devices and procedures, essentially replacing wet and cadaver labs.
In 2018, Allan co-founded Woodside Medical, an incubator helping commercialize U.S. medical technologies in China, with partnerships in Shanghai and Suzhou.
Allan has been founder, Chairman, CEO, or investor in over 80 medtech, biotech, and diagnostic startups. He was a co-founder and Chairman of Nanostim, developer of a Leadless Cardiac pacemaker, which was acquired by St. Jude Medical in 2013, and co-founder of Hyalex Surgical, Inc, developer of a novel artificial cartilage for total joint replacements, and is Chairman of Celero Medical, Noctrix Medical, and
Allan speaks frequently at conferences, universities, and government programs on trends and developments affecting early stage biotech and medical device investing. Allan developed medical device curriculum for Steve Blank’s inaugural groundbreaking program at University of California San Francisco to teach the Lean LaunchPad™ startup methodology in the medical device sector (LLP). He worked with Steve to bring LLP to the National Institutes of Health. LLP has also been adopted by the National Science Foundation as a core curriculum (i-Corps) for entrepreneurs. Previously, Allan served on the boards of directors of both the Kauffman Foundation’s Angel Capital Association and Angel Resource Institute, where he also served as Chairman.
Jun has over a decade of experience in biomedical innovation and venture capital investment. At Joyance Partners, Jun shaped the investment strategy for health-tech and biotech areas, led the “Inception” program to bridge the relationships between academia and venture, and led more than two dozens of investments globally. So far, Jun has led or been involved in over 50 early-stage investments in the field of healthcare, medtech and biotechnologies and served two board roles. Jun is a mentor in multiple innovation ecosystems, including Singularity University and Healthtech Capital. Jun received her PhD degree in molecular physiology from UCLA.
Bill is a Venture Partner with Genoa Ventures and a faculty member in the Department of Lab Medicine at the University of California, San Francisco (UCSF). Bill is a respected expert in both basic research and clinical lab application development with a strong concentration on cytometry, optical imaging and genomic technologies. Through strategic partnerships with companies like Becton Dickinson, Zeiss, Danaher and Sony, his lab designed, tested and/or validated over 20 different commercial products. Examples include the FACS Aria, FACS Canto, Sony Spectral Flow Cytometer, Meta Spectral Confocal, quantum dots, and Cytobank. His academic career includes a PhD in Biophysics and an MS in Biochemistry, past joint appointments at UC Berkeley and the Lawrence Berkeley National Lab, three honorary doctorates, and authorship of over 100 peer-reviewed publications.
On the venture side, Bill has co-founded ten biotech startups and has led investment in dozens of others, usually in the seed or series A stage. Example companies include Accuri Cytometers, Zephyrus, Mission Bio, Fluent, Slingshot, CellFe, and Akadeum. Bill is a current board member for five companies, has served as Venture Partner with two Bay Area venture groups focused on early-stage investment, and is closely affiliated with four life tech incubators.
Julia has been working in the Venture Capital Industry for more than 5 years, she is experienced in investor relationship management with the main focus on the impact investments in companies working to promote longevity and healthspan.
Julia is passionate about Biohacking. She is the Co-Organiser of Biohacking Congress, the international platform dedicated to furthering the advancement of Biohacking, Health Optimization, Longevity, Wellness, BioTech, and HealthTech.
I made my first early-stage investment in the late '90s before angel investing turned into an industry with incubators, accelerators, and syndicates. Angel investing enables me to time travel. Every day I get to see the future.
As a serial entrepreneur, I know the challenges of building a business, raising money, and if we're fortunate, finding a path to a solid exit.
My primary investing focus is investing in early-stage companies that will make a positive contribution towards healthier people and our planet. I typically invest as a syndicate member, though I make an occasional direct investment.
Mr. Moughrabie is the Managing Partner of ATMOS Ventures, focusing on developing Deep Technologies for large enterprise applications. Having facilitated over EUR 5 Billion in global investment transactions, Mr. Moughrabie is responsible for developing and implementing ATMOS’ short and long term global strategy by investing in the disruptive digitization of all major industry sectors.
Mr. Moughrabie is a global pioneer in the industrial applications of Artificial Intelligence and Quantum Computing, advising governments and global Fortune 500 companies on the implementation of Deep Technology solutions.
Mr. Moughrabie also serves as a Deep Technology consultant to the film industry in the US and the UK.
Previously, Mr. Moughrabie was with Bank of America’s Hedge Fund Group. He specialized in multi asset products within the Capital Markets as well as Structured Derivatives, Risk Management, and formulating strategic alliances in the alternative investments space.
Mr. Moughrabie earned his BA in Economics from the University of Chicago.
Dr. Ella Li is the partner of ZGC Innovation fund, and also serves as the VP of ZGC Capital Corporation in Silicon Valley leading ZGC’s team in investment and incubator operation. Dr. Ella Li has 15+ years of experience in pharmaceutical and biotechnology sectors and has rich investment experiences in therapeutic investment opportunities. She has also rich experiences in digital health, AI and IOT sectors, and serves as a board advisor, consultant and mentor for many global accelerators, incubators and VCs.
Dr. Ella Li earned her B.S. and M.S. degrees from Peking University School of Pharmacy, and her Ph.D. from the University of Texas Health Science Centers. She completed her postdoctoral fellowship from Harvard Medical School, where she led five independent projects exploring novel therapeutic targets for metabolic disease. Ella has extensive publications in prestigious journals with IMF over 10 including Nature Communication, Cell Metabolism, Journal of Clinical Investigation, PNAS, Molecular Cell, Diabetes, etc. with 500+ citations.
Ingrid is an Investment Director with Finistere Ventures. She has spent the last decade in agtech innovation and entrepreneurship holding roles in business development, strategic advisory, technology development, and venture capital.
Within the firm, Ingrid focuses on the application life sciences technologies within ag and food. Beyond her work with Finistere, Ingrid is passionate about public science communication, and DEI within STEM. Ingrid is an advisor to several accelerators and sits on the advisory boards of AgTech Next and Kroger’s Zero Hunger, Zero Waste Foundation Fund.
Michael O’Donnell is a partner in the firm’s Palo Alto office, specializing in corporate and securities law. He has more than 30 years of experience providing general corporate representation to biopharmaceutical and other life sciences companies. He offers particular expertise in venture capital financings, public offerings, mergers and acquisitions, strategic alliances, technology licensing, and corporate spin-out transactions. He represents numerous public and private biopharmaceutical, medical device, diagnostic, and instrumentation companies.
Michael was the founding attorney and lead attorney on the initial public offerings for companies such as Illumina, Neurocrine Biosciences, Cytokinetics, Cassava Sciences, Sequana Therapeutics, Ciphergen Biosystems, NeurogesX, Argonaut Technologies, and Microcide Pharmaceuticals.
Anam is a Principal at Purple Sage Ventures, an early-stage fund investing in women and other underrepresented founders building products/services that reimagine wellness, bolster business and personal productivity, and innovate supply chains.
Anam received her venture training from Amplifyher Ventures. Prior to investing, she co-founded the Art Department at Reliance Industries, India’s largest private-sector conglomerate and Jio Plaform’s parent company.
Anam holds a BBA in Finance and Accounting from Emory University, a Master’s in Art Business from Sotheby’s Institute of Art, and an MBA from Columbia Business School.
Rahul has a track record of managing pharmaceutical, medical device and digital health businesses across geographies. Currently, at Medicspot, Rahul believes that we are creating health technologies in communities that will transform how we access and engage with healthcare, so the right care at is available at the right time from the right clinician.
David is a pioneer and passionate leader of the venture capital ecosystem in Silicon Valley. David founded Silicon Valley’s largest entrepreneur community SVE. He founded several large developer communities including Silicon Valley Developer Network (SVDN), Silicon Valley Android Developers. He is also serving or served as an advisor for DocuSign, Ehouse Capital, Peakview’s Fund of Fund. He hosted interviews with leaders in the venture ecosystem for SVE.io David Cao was the Founder & CEO of GWC US (Sold to holding company); the founding president of the Silicon Valley Entrepreneur Toastmaster Club; founder and CEO of ExtendLogic (Acquired by BeyondSoft). Prior, he was the VP of Engineering at PlayPhone (Acquired by Gungho), a leading mobile entertainment in the USA, and Engineering lead for LightSurf, acquired by VeriSign for 274M USD. He has consulted for many firms including Oracle, ETravel, IBM Global Services, Sun Microsystems, OCBC Bank, and Reuters Asia.
|10:00 - 10:20 am PT||Introduction from Organisers||Julia Smila, Co-Founder of Unicorn Lab|
|10:05 - 11:00 am PT||Panel Discussion: "The Hottest Trends in HealthTech Investment."||See the section Speakers|
|11:00 - 11:15 am PT||Introduction of Investors||See the section Investors|
|11:15 - 12:45 pm PT||Claridream||Alex Kohen|
|12:45 - 12:15 pm PT||Wellness 4 Humanity||Lian Pham|
|12:15 - 12:45 pm PT||VidaLuz||Jessa Robuck|
|12:45 - 1:15 pm PT||Trusty.care||Jo Schneier|
I love BiohackingCongress in Silicon Valley because each speaker seems to be getting short and to the point like information-dense. Then you bring the panels up so we can interact with them. I love it. Great speakers, you brought a really good mix.I sit here knowing a lot of this information, it's like refreshing in my brain, so you guys did an incredible job!
I really enjoyed the lineup of speakers that we had this weekend. I’ve learned so much from them - panels, presentations, and different topics. We went beyond biohacking. So I really enjoyed this weekend. I will be at BiohackingCongress in Miami. And Miami in October is beautiful, the weather starts to get nice. So Miami in October is an incredible place to biohack together. I want to see you there!
It was so wonderful getting to see fellow speakers and biohacking companies together again despite the challenges of 2020. I'm always looking for opportunities to learn more from and connect with specialists and this event in Menlo Park allowed me to do just that!
I'm still buzzing from the Biohacking Congress event in Menlo Park last week! The speakers were incredibly knowledgeable and provided such value in their lectures, the vendors were extremely high-quality offering biohacking goodies to take home, the attendees were just lovely, and it was so refreshing to connect in-person with my biohacking fam! I can't wait to attend the next Biohacking Congress in the Spring!
The BiohackingCongress brings together groups of people who otherwise wouldn't meet and helps to overcome boundaries between health, business, and science.
BiohackingCongress in London gathered all the European most influential biohackers, experts, and leaders in one place. To share ideas, insights, and trends. The event was valuable for its speakers’ content. But almost underappreciated is the communications and networking part in non-formal conversations during the breaks. So many valuable topics and themes were discussed before and after the official part. Two thumbs up!
Great team with amazing energy. Really supportive, I pitched at their event, they helped prepare me with some training session and great mentors. Thank you, BiohackingCongress!
Thank's to Julia and the team at the BiohackingCongress for a great event. The Recharge team had a great time showing the FlexBeam, presenting on red light therapy and meeting all the top speakers and biohackers - we are looking forward to the next event - very well organized and a lot compacted into one day. Inspiring!
I know the team from Biohacking Congress for a long time; they are top-level professionals with tons of experience, connections, and lots of energy to provide superior service to their clients. They are particularly strong in helping companies in their Business Development activities in the USA and have a very strong network of investors here.
It was a pleasure being at such a well hosted and run event! I go to so many startup pitch events, and this was one of my favorites. Informative and engaging throughout, and the investors asked fantastic questions.
Love these guys what they are about and changing the world for a better place!!